Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma #mmsm #cellulartherapy #CARTsm https://www.prnewswire.com/news-releases/janssen-announces-unblinding-of-phase-3-cartitude-4-study-of-carvykti-cilta-cel-as-primary-endpoint-met-in-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma-301732398.html
Out in @CircAHA today, we use high quality #CHIP calls to show that IL6 receptor signaling modulates association between CHIP and CVD in 'full' UK Biobank dataset. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062126 https://twitter.com/DrFlashHeart/status/1617607601201774592
Last week, I shared how we derived CHIP calls in the UK Biobank (N ~450k).
In a study out today in Circulation (@CircAHA), we use these CHIP calls to contribute to an ongoing debate regarding IL-6 signaling mediating the association between CHIP & CAD.
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062126
An inspiration for the new year! Dr. Alex Herrera was on the @cityofhope "Expanding Hope" float in the #roseparade2023 . The mother of one of his patients walked alongside the float for 2.5 miles throwing him kisses to give him thanks and gratitude. http://bit.ly/3vQX2Do
Excited that our efforts, led by @tal_sella and @AnnPartridgeMD, to study patients’ perspectives on testing for #CHIP is now published @BloodAdvances https://ashpublications.org/bloodadvances/article/6/24/6151/486674/Patient-perspectives-on-testing-for-clonal